JAKARTA – PT Merck Tbk (MERK), engaging in healthcare announced its stable first semester 2017 result. Merck managed to maintain its sales and net profit in this period.
In first half 2016, Merck’s net sales and net profit noted Rp 577.96 billion and Rp 97 billion, respectively. For the first six months of 2017, Merck posted a slight growth both in the net sales and net profit to Rp 606.47 billion and Rp 100.64 billion, respectively.
Based on products, the sales of prescription drug (biopharma) in this period noted Rp 238.53 billion and over-the-counter drugs (consumer health) as much as Rp 320.75 billion, while others noted Rp 47.19 billion. While in the same period in 2016, the contribution from pharmaceutical product noted Rp 226.91 billion, followed by consumer health Rp 298.59 billion and others Rp 52.46 billion.
The indonesian healthcare and pharmaceutical industry is regarded to contain rewarding opportunities for the business. Research conducted by frost & Sullivan shows that Indonesia’s healthcare market could increase more than double between 2012 and 2018 and, supported by higher demand for medicines to treat lifestyle-related diseases such as diabetes and cardiovascular illnesses. (LM)